The Effectiveness of Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma

December 22, 2019 updated by: Abul Khayer, Chittagong Medical College
Outpatient department of cmch, ceitc,cimch POAG patients enrolled for the study.

Study Overview

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Chittagong
      • Dhaka, Chittagong, Bangladesh
        • Facuity of basic science and para clinical science
    • Chokhbazar
      • Chittagong, Chokhbazar, Bangladesh
        • Facuity of basic scienceand para clinican science

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • IOP 22_34mmof Hg,newly diagnosed case, bilateral POAG patients Patients.

Exclusion Criteria:

  • pregnant and lactating women, infection, any eye surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A
Latanoprost
To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
Other Names:
  • Brimonidine
Other: Group B
Brimonidine
To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
Other Names:
  • Brimonidine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
More than 20% IOP reduction
Time Frame: 0_3 months
From baseline to month 3
0_3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse reaction
Time Frame: O_3 months
Record every follow up period baseline to month 3.
O_3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 25, 2018

Primary Completion (Actual)

September 24, 2019

Study Completion (Actual)

October 5, 2019

Study Registration Dates

First Submitted

December 17, 2019

First Submitted That Met QC Criteria

December 17, 2019

First Posted (Actual)

December 19, 2019

Study Record Updates

Last Update Posted (Actual)

December 26, 2019

Last Update Submitted That Met QC Criteria

December 22, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on To See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma Patients

Clinical Trials on Drugs, Investigational

Subscribe